key: cord-0850390-b6l1n0yy
authors: Robinson, Philip C.; Kim, Alfred H.J.
title: Addressing the challenges of the SARS-CoV-2 pandemic in patients affected by autoimmune and rheumatic disease
date: 2021-02-17
journal: Best Pract Res Clin Rheumatol
DOI: 10.1016/j.berh.2021.101664
sha: b64078ad38d1dbc60d7b5f9b87468122884735a6
doc_id: 850390
cord_uid: b6l1n0yy

nan

Addressing the challenges of the SARS-CoV-2 pandemic in patients affected by autoimmune and rheumatic disease

The novel coronavirus (SARS-CoV-2) pandemic has caused a massive health and economic upheaval for the world's population and no more so than for those with autoimmune and rheumatic disease. Initially, there was great concern that those with autoimmune disease would fair poorly. The initial stark fears about poor prognosis with immune-suppressing drugs has given way to a complex scenario of evolving information. It seems that some patients are at increased risk from prescribed medications such as sulfasalazine and B-cell depleting therapies. However, there may well be medications that improve outcomes, potentially agents such as anti-TNF or JAK inhibitors. Importantly, patients with rheumatic disease are not immune to the risk factors present in the general population such as advancing age and comorbidity.

While the impact of COVID-19 has been detrimental for many and highly disruptive for all, the response by the rheumatology community has been an extraordinary example of our cohesiveness and willingness to collaborate to obtain rigorous answers for our patients. Numerous research groups rapidly organized across the globe to address critical questions regarding COVID-19 in rheumatic disease patients, including the COVID-19 Global Rheumatology Alliance. Collectively, in less than a year, our community has been able to answer many important questions, and many of these answers are detailed within this volume: the epidemiology of those with various rheumatic diseases contracting COVID-19 and the likelihood of developing severe COVID-19; determining whether immunomodulatory agents used in rheumatic diseases may help attenuate COVID-19 disease severity; identifying how racial, ethnic, and socioeconomic disparities impact rheumatic disease patients with COVID-19; identifying how the molecular testing platforms for SARS-CoV-2 have evolved and performed; and identifying immunologic mechanisms that drive the severe manifestations of COVID-19. This has resulted in a rapid rate of high-quality publications and initiation of numerous clinical trials. Ultimately, this speaks to the research community's ability to collectively respond rapidly to this crisis.

The pandemic will continue to impact the world of rheumatology for many years to come, particularly if SARS-CoV-2 becomes endemic. Adequate vaccination will provide some level of protection, but there is enough extensive skepticism to suggest that herd immunity will be very challenging to achieve. With that backdrop, it is salient to consider what the 'new normal' in rheumatology might look like. There will be more extensive use of telehealth, but this was a trend already emerging especially in countries where the tyranny of distance impaired the provision of good care like in Australia. It is apposite to consider if B-cell depleting therapies and widely used anti-rheumatic drugs such as sulfasalazine will be used less due to their association with poorer outcomes in patients with rheumatic disease who develop COVID-19. This will depend both on the level of COVID-19 in the community and whether there are reasonable alternatives available. There remain several outstanding questions that require our community to maintain our momentum in answering them. First, the impact of immunomodulatory therapies remains unclear despite substantial amounts of published data. This might be best exemplified with anti-IL-6 therapies, as differences in patient population and timing of administration may be critical in its success or failure as a late-stage intervention. Second, diversity in diagnostic testing platforms have led to confusion, leading to improper interpretation by clinicians. Additionally, serology testing continues to have unclear potential. Finally, the important question of the efficacy and safety of COVID-19 vaccines in rheumatic disease patients deserves much deeper examination. There are a range of different vaccine technologies being used to develop COVID-19 vaccines, some of which are being used for the very first time. Consequently, providers are left in the uncomfortable position of providing counsel to rheumatic disease patients despite a complete lack of data. Efforts are already underway to address these questions though, and similar to the initial efforts by the rheumatology community, we hope that answers to these questions will emerge quickly.

While there has been much achieved in the first year since the pandemic was declared, the task now becomes more challenging. The questions become more technically difficult to answer; for example, what effect does the myriad of rheumatic diseases and anti-rheumatic medications have on efficacy and durability of vaccine responses? In addition, the interface between the science of vaccine technology and the practicality of getting people to be vaccinated becomes very relevant. Efficacy and safety will remain unaddressed if people will not come forward to receive their vaccine.

Order of chapters -COVID-19 and Rheumatology

COVID-19) in people with rheumatic disease: epidemiology & outcomes Chapter 2 -The Racial/Ethnic and Sociocultural Aspects of the Pandemic in Rheumatology Chapter 3 -The protective effect of rheumatic disease agents

Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? Chapter 5 -Laboratory evaluation of SARS-CoV-2 in the COVID-19 pandemic Chapter 6 -Managing patients with tele-rheumatology during a pandemic Chapter